TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03125733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submucosal tunneling endoscopic septum division
Description: STESD includes 4 steps:~1. Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~2. Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~3. Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~4. Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips.
Study: NCT02378805

Intervention type: DRUG
Intervention: HMG-Coenzyme inhibitor (statin)
Description: observational study!

Intervention type: DRUG
Intervention: Spironolactone
Description: observational study!

Intervention type: DRUG
Intervention: Spironolactone
Description: observational study!

Intervention type: DRUG
Intervention: Spironolactone
Description: observational study!

Intervention type: DRUG
Intervention: Spironolactone
Description: observational study!

Intervention type: DRUG
Intervention: Paricalcitol
Description: observational study!

Intervention type: DRUG
Intervention: Paricalcitol
Description: observational study!

Intervention type: DRUG
Intervention: Paricalcitol
Description: observational study!

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: observational study!
Study: NCT03255954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling for University Counseling Centers
Description: Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
Study: NCT02572336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THR-18
Description: THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
Study: NCT02069158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: iv administration
Study: NCT02373397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cacicol20
Description: Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle only in identical packaging, with identical dosage and administration route.
Study: NCT03680248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fasting
Description: Subjects will fast throughout the experiment.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fasting
Description: Subjects will fast throughout the experiment.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat+Glucose
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat+Glucose
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat+Fructose
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat+Fructose
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
Study: NCT02572336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a THR-18 lookalike, to be administered with tPA.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA is a thrombolytic agent. tPA is not an investigational drug.
Study: NCT04488822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: 400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
Study: NCT02572336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA is a thrombolytic agent. tPA is not an investigational drug.
Study: NCT02591420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for VRC01
Description: Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
Description: ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
Description: ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) (regimen will vary within countries and by patient)
Description: ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
Study: NCT00197028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02D
Description: 3-dose intramuscular injection in the thigh

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRActHib™
Description: 3-dose intramuscular injection in the thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B®
Description: 3-dose intramuscular injection in the thigh.
Study: NCT00247624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Eszopiclone 3 mg every night for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 20 mg every morning for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine 20 mg every morning for 9 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo every night for 8 weeks
Study: NCT01915199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Care
Description: Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
Study: NCT01702389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study: NCT03680248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
Study: NCT02412384

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: Flow cytometry (FCM)
Description: Use FCM to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT02830165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT01440725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet-rich plasma (PRP)
Description: 4-8cc, a single dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evacuation of haematoma
Description: Evacuation of the haematoma, a single procedure
Study: NCT06181851

Intervention type: OTHER
Intervention: Analysis of microbiome and metabolomics
Description: Analysis of microbiome and metabolomics through the assessment of blood and semen parameters

Intervention type: OTHER
Intervention: Analysis of microbiome and metabolomics
Description: Analysis of microbiome and metabolomics through the assessment of blood and semen parameters

Intervention type: OTHER
Intervention: Analysis of microbiome and metabolomics
Description: Analysis of microbiome and metabolomics through the assessment of blood and semen parameters
Study: NCT04464447

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: The treatment ACT for Health in Adolescents (AHEAD) is an ACT-based Group intervention consisting of 9 modules (27 hours in total) delivered over a period of 3 months, with a follow-up meeting (3 hours) 3 months after the last module. Six to eight patients participate in each treatment Group. An information meeting (3 hours) for close relatives is held at the beginning of the Group treatment and the adolescents and their parents were invited to a 1½-hour individual consultation after the 8th module.
Study: NCT01363843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX6
Description: FOLFOX6

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT with concurrent chemotherapy
Description: IMRT 50.4Gy with chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT00820105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX10059
Description: Oral administration
Study: NCT02412384

Intervention type: OTHER
Intervention: RT-PCR
Description: Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
Study: NCT00820105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADX10059 Matching Placebo
Description: Oral administration
Study: NCT03885284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~* Irinotecan 150 mg/m2 IV day 1~* Oxaliplatin 85 mg/m2 IV day 1~* Leucovorin 400 mg/m2 IV day 1~* 5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~* Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~* Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiation
Description: Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiation
Description: Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
Study: NCT02948166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty with stenting of the femoral artery
Description: A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
Study: NCT05312502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth Ball
Description: During labour, the pregnant woman was positioned using a birth ball.
Study: NCT02522637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each \< 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%.
Study: NCT03542214

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Calcium electroporation
Description: Patients with inoperable colorectal cancer will be treated with calcium electroporation
Study: NCT00837460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: 4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
Study: NCT01371682

Intervention type: DRUG
Group type: OTHER
Intervention: Ropinirole XL
Description: Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropinirole XL
Description: Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
Study: NCT01642160

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: additional educational material
Description: The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: participants will receive education from staff nurses as needed.
Study: NCT03423693

Intervention type: OTHER
Intervention: No any intervention
Description: No any intervention is applied to any groups in this study

Intervention type: OTHER
Intervention: No any intervention
Description: No any intervention is applied to any groups in this study

Intervention type: OTHER
Intervention: No any intervention
Description: No any intervention is applied to any groups in this study

Intervention type: OTHER
Intervention: No any intervention
Description: No any intervention is applied to any groups in this study
Study: NCT01529268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DR cysteamine bitartrate capsule
Description: * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DR cysteamine bitartrate placebo
Description: * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline
Study: NCT01522053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter-over-needle
Description: Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter-through-needle
Description: Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
Study: NCT03181555

Intervention type: OTHER
Group type: OTHER
Intervention: Exploratory
Study: NCT00232882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan Thiazide
Description: Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol Thiazide
Description: Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazide Candesartan
Description: Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
Study: NCT01937338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7624
Description: nebuliser solution; 20 mg/mL for inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nebuliser solution for inhalation